Cargando…

Enhancing Osteoporosis Treatment through Targeted Nanoparticle Delivery of Risedronate: In Vivo Evaluation and Bioavailability Enhancement

Risedronate-loaded mPEG-coated hydroxyapatite, thiolated chitosan-based (coated) and non-coated nanoparticles were tested for their potential effects in the treatment of osteoporosis. The prepared nanoparticles were evaluated for their bone-targeting potential by inducing osteoporosis in female Wist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saifi, Zoya, Shafi, Sadat, Ralli, Tanya, Jain, Shreshta, Vohora, Divya, Mir, Showkat Rasool, Alhalmi, Abdulsalam, Noman, Omar M., Alahdab, Ahmad, Amin, Saima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534762/ https://www.ncbi.nlm.nih.gov/pubmed/37765307 http://dx.doi.org/10.3390/pharmaceutics15092339

Ejemplares similares

Bioavailability enhancement studies of amoxicillin with Nigella
por: Ali, Babar, et al.
Publicado: (2012)

Once-monthly risedronate for postmenopausal osteoporosis
por: Casadei, Kristina, et al.
Publicado: (2010)

Octanoic acid a major component of widely consumed medium-chain triglyceride ketogenic diet is detrimental to bone
por: Jain, Shreshta, et al.
Publicado: (2021)

Review of the safety and efficacy of risedronate for the treatment of male osteoporosis
por: Bobba, Raja, et al.
Publicado: (2007)

Development and Characterization of Terbinafine-Loaded Nanoemulgel for Effective Management of Dermatophytosis
por: Phagna, Mayank, et al.
Publicado: (2023)

Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study
por: Cho, Yong Ho, et al.
Publicado: (2020)

Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications
por: Jain, Shreshta, et al.
Publicado: (2021)

Risedronate’s Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis
por: Gates, Brian J., et al.
Publicado: (2012)

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
por: Masud, Tahir, et al.
Publicado: (2009)

Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA
por: Eisman, John A., et al.
Publicado: (2023)

Decoding the bidirectional relationship between gut microbiota and COVID-19
por: Ralli, Tanya, et al.
Publicado: (2023)

Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
por: Moro-Álvarez, María J, et al.
Publicado: (2008)

Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation
por: Kinov, Plamen, et al.
Publicado: (2012)

The Therapeutic Effectiveness of the Coadministration of Weekly Risedronate and Proton Pump Inhibitor in Osteoporosis Treatment
por: Tanaka, Mizue, et al.
Publicado: (2014)

Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials
por: Shigematsu, Takashi, et al.
Publicado: (2017)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
por: Rackoff, Paula
Publicado: (2009)

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
por: McClung, M. R., et al.
Publicado: (2012)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France
por: Hiligsmann, M., et al.
Publicado: (2019)

Linagliptin in Combination With Metformin Ameliorates Diabetic Osteoporosis Through Modulating BMP-2 and Sclerostin in the High-Fat Diet Fed C57BL/6 Mice
por: Nirwan, Nikita, et al.
Publicado: (2022)

Colon-targeted quercetin delivery using natural polymer to enhance its bioavailability
por: Singhal, Anil, et al.
Publicado: (2011)

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data
por: McClung, Michael R., et al.
Publicado: (2012)

Effects of teriparatide compared with risedronate in the treatment of osteoporosis: A meta-analysis of randomized controlled trials
por: Yang, Chengzhi, et al.
Publicado: (2020)

Flavonoid Bioavailability and Attempts for Bioavailability Enhancement
por: Thilakarathna, Surangi H., et al.
Publicado: (2013)

Prevalence of osteoporosis and osteopenia in an apparently healthy Indian population - a cross-sectional retrospective study
por: Kaushal, Neelam, et al.
Publicado: (2018)

Effects of Risedronate on Osteoarthritis of the Knee
por: Iwamoto, Jun, et al.
Publicado: (2010)

A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis
por: Soen, Satoshi, et al.
Publicado: (2020)

Zoledronic acid is effective in the management of migratory osteoporosis unresponsive to conservative treatment and risedronate: A case report
por: Evangelatos, Gerasimos, et al.
Publicado: (2021)

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
por: McClung, M. R., et al.
Publicado: (2012)

Comparative Effects of Teriparatide and Risedronate in Glucocorticoid-Induced Osteoporosis in Men: 18-Month Results of the EuroGIOPs Trial
por: Glüer, Claus-C, et al.
Publicado: (2013)

Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis
por: Calabria, S, et al.
Publicado: (2016)

Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis
por: Chung, Ho Yeon, et al.
Publicado: (2013)

Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials
por: Mawatari, T., et al.
Publicado: (2016)

Efficacy of topical risedronate and risedronate - Eudragit E complex in a model of cutaneous leishmaniasis induced by Leishmania (Leishmania) amazonensis
por: Peralta, Ma. Florencia, et al.
Publicado: (2021)

Risedronate inhibits human osteosarcoma cell invasion
por: Xin, Zeng Feng, et al.
Publicado: (2009)

Crystallization Products of Risedronate with Carbohydrates and Their Substituted Derivatives (†)
por: Kos, Jiri, et al.
Publicado: (2011)

Preparation of Risedronate Nanoparticles by Solvent Evaporation Technique
por: Vaculikova, Eliska, et al.
Publicado: (2014)

Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020)

Risedronate-loaded aerogel scaffolds for bone regeneration
por: El-Wakil, Nahla, et al.
Publicado: (2022)

An open‐label randomized study of the relative absorption of gastro‐resistant risedronate taken fasted or with food versus immediate‐release risedronate
por: Kleinermans, Diane, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qet32n5uuu5v29ss8ba40ejh3o